Can You Guess FTSE 100's Hidden Gem?

AstraZeneca stands out as an exciting growth stock within the FTSE 100, driven by its robust pipeline of new medicines and strong financial performance. In 2024, the company saw significant growth across its departments, with oncology revenue rising by 24% and respiratory and immunology by 25%. AstraZeneca anticipates the first Phase III data for seven new medicines in 2025, along with new indications for existing drugs. This momentum positions the company for sustained growth, making it an attractive choice for investors seeking both growth and dividend potential. Its commitment to transformative technologies further enhances its long-term prospects.

 

Source: Euronews, AstraZeneca, Morningstar